TREA

85277030 - INSTATAB

Follow

Information

  • Trademark
  • 85277030
  • Serial Number
    85277030
  • Filing Date
    March 25, 2011
    13 years ago
  • Transaction Date
    January 21, 2015
    9 years ago
  • Status Date
    June 03, 2013
    11 years ago
  • Published for Opposition Date
    September 04, 2012
    12 years ago
  • Location Date
    October 30, 2012
    12 years ago
  • Status Code
    606
  • Current Location
    INTENT TO USE SECTION
    Employee Name
    EULIN, INGRID C
  • Attorney Docket Number
    VPBV002
    Attorney Name
    Christopher L. Graff
    Law Office Assigned Location Code
    M20
  • Owners
Information
Mark Drawing Code
4000
Mark Identification
INSTATAB
Case File Statements
  • CC0000: Color is not claimed as a feature of the mark.
  • GS0051: Pharmaceutical preparations and substances for the prevention, treatment and alleviation of stress; pharmaceutical preparations and substances for the prevention, treatment and alleviation of diabetes; pharmaceutical preparations and substances for controlling insulin levels; pharmaceutical preparations and substances for the prevention, treatment and alleviation of hypertension; pharmaceutical preparations and substances for the prevention, treatment and alleviation of angina; pharmaceutical preparations and substances for the cessation of smoking; pharmaceutical preparations and substances for the prevention and treatment of sexually transmitted diseases; pharmaceutical preparations and substances for the prevention and treatment of herpes; pharmaceutical preparations and substances for the prevention, treatment and alleviation of disorders, diseases, conditions and ailments of the central nervous system; pharmaceutical preparations and substances for the prevention, treatment and alleviation of depression; anti-depressants; pharmaceutical preparations and substances for the prevention, treatment and alleviation of sleep disorders; pharmaceutical preparations and substances for the prevention, treatment and alleviation of anxiety; pharmaceutical preparations and substances for the prevention, treatment and alleviation of disorders, diseases, conditions and ailments of the cardio-vascular system; pharmaceutical preparations and substances for the prevention, treatment and alleviation of acute myocardial infarctions; pharmaceutical preparations and substances for the prevention, treatment and alleviation of symptomatic congestive heart failure; pharmaceutical preparations and substances for the prevention, treatment and alleviation of asymptomatic left ventricular dysfunction; pharmaceutical preparations and substances, namely, fibrinolytic or thrombolytic agents; pharmaceutical preparations and substances for the prevention, treatment and alleviation of disorders, diseases, conditions and ailments of the respiratory system; pharmaceutical preparations and substances for the prevention, treatment and alleviation of disorders, diseases, conditions and ailments of the endocrine system; pharmaceutical preparations and substances for the prevention, treatment and alleviation of disorders, diseases, conditions and ailments of the immune system; pharmaceutical preparations and substances for the prevention, treatment and alleviation of disorders, diseases, conditions and ailments of the musculo-skeletal system, namely, bone diseases and bone degenerative conditions; pharmaceutical preparations and substances for the prevention, treatment and alleviation of pain and inflammation, namely, pain relief medication and anti-inflammatories; pharmaceutical preparations and substances for the prevention, treatment and alleviation of migraines; pharmaceutical preparations and substances, namely, medicated skin care preparations for use in dermatology, namely, dermatitis and skin pigmentation diseases; pharmaceutical preparations and substances for use in oncology; pharmaceutical preparations and substances for use in ophthalmology; pharmaceutical preparations and substances for the treatment of polycystic ovary syndrome; pharmaceutical preparations and substances for the treatment of infertility; pharmaceutical preparations and substances for the prevention, treatment and alleviation of circulatory, neurologic, alimentary, auto-immune, pulmonary, musculoskeletal, lymphatic, gastrointestinal, bone sensory, viral, urinary, renal, infectious or metabolic diseases, illnesses, disorders or conditions
Case File Event Statements
  • 1/21/2015 - 9 years ago
    28 - ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY Type: ASCK
  • 1/22/2014 - 10 years ago
    27 - ATTORNEY REVOKED AND/OR APPOINTED Type: ARAA
  • 1/22/2014 - 10 years ago
    26 - TEAS REVOKE/APPOINT ATTORNEY RECEIVED Type: REAP
  • 6/3/2013 - 11 years ago
    25 - ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED Type: MAB6
  • 6/3/2013 - 11 years ago
    24 - ABANDONMENT - NO USE STATEMENT FILED Type: ABN6
  • 10/30/2012 - 12 years ago
    23 - NOA E-MAILED - SOU REQUIRED FROM APPLICANT Type: NOAM
  • 9/4/2012 - 12 years ago
    22 - OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Type: NPUB
  • 9/4/2012 - 12 years ago
    21 - PUBLISHED FOR OPPOSITION Type: PUBO
  • 8/15/2012 - 12 years ago
    20 - NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Type: NONP
  • 7/31/2012 - 12 years ago
    19 - LAW OFFICE PUBLICATION REVIEW COMPLETED Type: PREV
  • 7/31/2012 - 12 years ago
    18 - APPROVED FOR PUB - PRINCIPAL REGISTER Type: CNSA
  • 7/31/2012 - 12 years ago
    17 - EXAMINER'S AMENDMENT ENTERED Type: XAEC
  • 7/30/2012 - 12 years ago
    16 - NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED Type: GNEN
  • 7/30/2012 - 12 years ago
    15 - EXAMINERS AMENDMENT E-MAILED Type: GNEA
  • 7/30/2012 - 12 years ago
    14 - EXAMINERS AMENDMENT -WRITTEN Type: CNEA
  • 1/1/2012 - 12 years ago
    13 - NOTIFICATION OF FINAL REFUSAL EMAILED Type: GNFN
  • 1/1/2012 - 12 years ago
    12 - FINAL REFUSAL E-MAILED Type: GNFR
  • 1/1/2012 - 12 years ago
    11 - FINAL REFUSAL WRITTEN Type: CNFR
  • 12/16/2011 - 13 years ago
    10 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME
  • 12/16/2011 - 13 years ago
    9 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA
  • 12/16/2011 - 13 years ago
    8 - ASSIGNED TO LIE Type: ALIE
  • 12/14/2011 - 13 years ago
    7 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA
  • 6/14/2011 - 13 years ago
    6 - NOTIFICATION OF NON-FINAL ACTION E-MAILED Type: GNRN
  • 6/14/2011 - 13 years ago
    5 - NON-FINAL ACTION E-MAILED Type: GNRT
  • 6/14/2011 - 13 years ago
    4 - NON-FINAL ACTION WRITTEN Type: CNRT
  • 6/9/2011 - 13 years ago
    3 - ASSIGNED TO EXAMINER Type: DOCK
  • 3/29/2011 - 13 years ago
    2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM Type: NWOS
  • 3/29/2011 - 13 years ago
    1 - NEW APPLICATION ENTERED IN TRAM Type: NWAP